ProFibrix, a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, has appointed Jan Ohrstrom as its COO.
Dr Ohrstrom was previously part of the senior management team that took ZymoGenetics public, and played a key role in bringing recombinant human thrombin to the US market. Dr Ohrstrom will be based in Seattle, Washington, where ProFibrix has established a wholly owned subsidiary.
According to ProFibrix, its subsidiary ProFibrix Inc will facilitate the preparations of a global pivotal Phase II/III trial for the lead product Fibrocaps, to be conducted in 2009/2010. Additionally, it is expected to expand the company's reach to additional drug development expertise and at the same time provide easy access to US investors for the follow-up financing of ProFibrix.
Jaap Koopman, founder and CEO of ProFibrix, said: "We are delighted with the decision of Dr Ohrstrom to join ProFibrix. His extensive expertise in the management of drug development and business operations will be a tremendous asset to ProFibrix as we continue to move our products through clinical development towards commercialization and prepare for the next financing round early next year."
No comments:
Post a Comment